Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E2906||ECOG||Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy; Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)||Adult CIRB - Late Phase Emphasis||Available to Open|
|9924||ETCTN||A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)||Adult CIRB - Early Phase Emphasis||Available to Open|
|CALGB-10501||CALGB||A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease <br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|A021602||Alliance||Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041702||Alliance||A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011502||Alliance||A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|10315||ETCTN||A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas||Adult CIRB - Early Phase Emphasis||Available to Open|
|EA1181||ECOG-ACRIN||(CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response||Adult CIRB - Late Phase Emphasis||Available to Open|
|ANHL12P1||COG||A Randomized Phase II Trial of Brentuximab Vedotin (SGN35; NSC# 749710) or Crizotinib (NSC#749005; commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117||Pediatric CIRB||Available to Open|
|AREN03B2||COG||Renal Tumors Classification; Biology; and Banking Study||Pediatric CIRB||Available to Open|